Anixa Biosciences (ANIX) Depreciation & Amortization (CF) (2010 - 2020)
Anixa Biosciences' (ANIX) quarterly Depreciation & Amortization (CF) came in at $8858.0 in Q3 2020, down 40.48% YoY from $14882.0 in Q3 2019, and down 38.57% on a QoQ basis from $14420.0 in Q2 2020.
Anixa Biosciences (ANIX) Depreciation & Amortization (CF) (2010 - 2020) Analysis & Trends
Anixa Biosciences (ANIX) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $8858.0 in Q3 2020.
- Quarterly Depreciation & Amortization (CF) fell 40.48% year-over-year to $8858.0 in Q3 2020, while the trailing twelve-month figure through Apr 2021 was $8858.0 (down 84.95% YoY) and the FY2020 annual result came in at $38276.0, down 19.52% from the prior year.
- Depreciation & Amortization (CF) slipped to $8858.0 in Q3 2020, from $14420.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $14998.0 in Q1 2020 to a low of $2978.0 in Q2 2018.
- A 5-year average of $9516.7 and a median of $10505.0 in 2017 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2018 — Depreciation & Amortization (CF) plunged 72.36% — and 2019, when it surged 302.22%.
- Tracing ANIX's Depreciation & Amortization (CF) over 5 years: stood at $8418.0 in 2016, then soared by 32.1% to $11120.0 in 2017, then tumbled by 45.85% to $6021.0 in 2018, then jumped by 141.95% to $14568.0 in 2019, then tumbled by 39.2% to $8858.0 in 2020.
- The last three Depreciation & Amortization (CF) figures came in at $8858.0 (Q3 2020), $14420.0 (Q2 2020), and $14998.0 (Q1 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2020 | 8,858.00 |
| Jul 31, 2020 | 8,858.00 |
| Apr 30, 2020 | 14,420.00 |
| Apr 30, 2020 | 14,420.00 |
| Jan 31, 2020 | 14,998.00 |
| Jan 31, 2020 | 14,998.00 |
| Oct 31, 2019 | 14,568.00 |
| Oct 31, 2019 | 14,568.00 |
| Jul 31, 2019 | 14,882.00 |
| Jul 31, 2019 | 14,882.00 |
| Apr 30, 2019 | 11,978.00 |
| Apr 30, 2019 | 11,978.00 |
| Jan 31, 2019 | 6,130.00 |
| Jan 31, 2019 | 6,130.00 |
| Oct 31, 2018 | 6,021.00 |
| Oct 31, 2018 | 6,021.00 |
| Jul 31, 2018 | 5,045.00 |
| Jul 31, 2018 | 5,045.00 |
| Apr 30, 2018 | 2,978.00 |
| Apr 30, 2018 | 2,978.00 |